The research group proceeds the activity started in previous projects (FFC#21/2014, FFC#19/2016 and FFC#19/2020) on the resolvin D1 molecule (RvD1), an endogenous chemical mediator derived from omega-3 fatty acids, produced spontaneously to resolve inflammation and repair damaged tissues that is defective in cystic fibrosis (CF). RvD1 has therapeutic potential for persons with CF but appropriate formulations must be developed to progress with clinical development. This project focuses on developing formulations based on nanoparticles (sSNPs) that improve the stability and efficacy of RvD1 in reducing inflammation, mucus accumulation, lung damage and infection in CF. Researchers will evaluate the functionality of sSNP-RvD1 with preclinical studies both in CF mouse models and in leukocytes and epithelial cells obtained from CF volunteers. The results of these experiments will help define the potency and efficacy of sSNP-RvD1.

XIX Convention FFC Ricerca – download here a brief presentation of the project